Active ETFs continue to rise in significance for investors, with flows on track for another record amid more and more launches. Amid that rise for the category, certain ETFs have stood out of late, the T. Rowe Price Health Care ETF (TMED) included. The fund is not only performing well in the last month, but also sending a buy signal according to its buy chart. See more: Investing in Biotech? Look to Active for Index Performance Dispersion TMED charges a 44 basis point fee to actively invest in healthcare st ...

Healthcare innovation and biotechnology are standing out right now as areas with a lot of promise for investors. September's rate cut has brightened prospects, while R&D, boosted by AI, is driving new drug discoveries. Health and biotech ETFs and investing could make for a worthwhile consideration as equities uncertainty rises. Amid that interest, investors may want to consider how active investing can outperform passive biotech approaches to life sciences in some key ways. See more: Rising Active ETF TCAF ...

Core Viewpoint - T. Rowe Price has launched three new active transparent equity ETFs, expanding its lineup to a total of 22 offerings, aimed at providing long-term capital appreciation through sector-specific investments [1][2][4]. Group 1: New ETF Launches - The newly launched ETFs are T. Rowe Price Financials ETF (TFNS), T. Rowe Price Health Care ETF (TMED), and T. Rowe Price Natural Resources ETF (TURF) [1][2]. - Each ETF has an expense ratio of 0.44% and seeks to invest at least 80% of its net assets in their respective sectors [2][3][4]. Group 2: Investment Strategies - TFNS focuses on the financial services industry, typically maintaining a portfolio of 50-70 companies [2]. - TMED targets health care innovations, with a diversified portfolio of 100 to 150 stocks across biotechnology, pharmaceuticals, and health care services [3]. - TURF invests in natural resource companies, primarily in energy, minerals, and agriculture, holding 60-80 securities globally [4]. Group 3: Company Background - T. Rowe Price, founded in 1937, manages USD $1.62 trillion in assets as of May 31, 2025, and is known for its investment excellence and active management approach [5]. - The firm has a commitment to growing its active ETF business and aims to deliver compelling investment ideas through rigorous global research [5].